1. The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis
- Author
-
Manuel Scimeca, Manuela Montanaro, Rita Bonfiglio, Lucia Anemona, Enrico Finazzi Agrò, Anastasios D. Asimakopoulos, Roberto Bei, Vittorio Manzari, Nicoletta Urbano, Erica Giacobbi, Francesca Servadei, Elena Bonanno, Orazio Schillaci, and Alessandro Mauriello
- Subjects
prostate cancer ,ETS homologous factor ,metastasis ,histological marker ,Medicine (General) ,R5-920 - Abstract
The main aim of this study was to investigate the risk of prostate cancer metastasis formation associated with the expression of ETS homologous factor (EHF) in a cohort of bioptic samples. To this end, the expression of EHF was evaluated in a cohort of 152 prostate biopsies including primary prostate cancers that developed metastatic lesions, primary prostate cancers that did not develop metastasis, and benign lesions. Data here reported EHF as a candidate immunohistochemical prognostic biomarker for prostate cancer metastasis formation regardless of the Gleason scoring system. Indeed, our data clearly show that primary lesions with EHF positive cells ≥40% had a great risk of developing metastasis within five years from the first diagnosis. Patients with these lesions had about a 40-fold increased risk of developing metastasis as compared with patients with prostate lesions characterized by a percentage of EHF positive cells ≤30%. In conclusion, the immunohistochemical evaluation of EHF could significantly improve the management of prostate cancer patients by optimizing the diagnostic and therapeutic health procedures and, more important, ameliorating the patient’s quality of life.
- Published
- 2022
- Full Text
- View/download PDF